ClinicalTrials.gg
Status unknownNCT02909088Updated Oct 26, 2016

Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

A Phase 2/3 interventional study of Ecopipam 50mg and Ecopipam 100mg in Stuttering, Adult, Childhood-onset Fluency Disorder and Speech Disorders, sponsored by Gerald Maguire, MD. Status unknown at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-10-26.

Sponsored by Gerald Maguire, MD · Phase 2/3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Stuttering with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Stuttering · United States.

Planned enrollment
25th of 27
10 · median 68
Started
2016
the only one that year
Phase 2/3
2 of 35
none open now
Registered
12th of 35
by date
Lead sponsor
1 of 35
Gerald Maguire, MD

Among the 35 studies in Stuttering with a site in United States, this one is the 25th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2/3, and was the 12th registered.

Stuttering

74 studies on the registry are indexed under Stuttering; 23 are open to participants now.

Browse Stuttering studies →

Open to participants now

17 of the 35 studies in Stuttering with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Stuttering studies recruiting now, 3 (16%) set no upper age limit and 15 (79%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Stuttering with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms.

It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.

03

Conditions studied

  • Stuttering, Adult
  • Childhood-onset Fluency Disorder
  • Speech Disorders
  • Language Disorders
  • Communication Disorder

Keywords

  • stuttering
  • childhood onset fluency disorder
  • ecopipam
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects can be enrolled in the study only if they meet all of the following criteria:

  1. Subjects must satisfy criteria for childhood onset fluency disorder (stuttering).
  2. The nature of stuttering must be developmental in origin with the onset prior to ten years of age.
  3. Subjects must have a score of moderate or higher on the SSI-IV.
  4. Women of are eligible to participate as long as they are practicing a medically accepted form of (i.e. condom with spermicide or diaphragm, oral or depot contraception, or an intrauterine device).
  5. Subjects will be male or female from the ages of 18-60.
  6. Subject must have a MADRS total score of ≤ 13 (normal mood)
  7. Subjects will be of only English speaking.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study for any of the following reasons:

  1. Adult individuals who lack capacity to consent for themselves.
  2. Stuttering related to a known neurologic cause (e.g. head trauma, stroke).
  3. Unstable medical or psychiatric illness.
  4. Active substance abuse within three months prior to study inclusion.
  5. Any illness that would require the concomitant use of a CNS active medication during the course of the study.
  6. Subjects with Parkinson's dementia or other degenerative neurologic illness.
  7. Suffer from irregular heart rate or seizures
  8. Subjects who are pregnant or nursing an infant.
  9. Subject with a MADRS ≥ 14
  10. Breastfeeding a child during the course of the study or for one month following completion
  11. It is the investigator's opinion that the subject poses a significant suicide risk by the following criteria:

    1. It is the investigator's opinion that the subject may be at risk of suicide.
    2. the subject responds "yes" to question #4 (Active Suicidal Ideation with Specific Plan and Intent) on the Baseline Visit of the Columbia Suicide Severity Rating Scale (C-SSRS), if the most recent episode occurred within the past 12 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Ecopipam 50mg

    50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.

    Drug: Ecopipam 50mg · Drug: Ecopipam 100mg

  • Experimental
    Ecopipam 100mg

    If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.

    Drug: Ecopipam 50mg · Drug: Ecopipam 100mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the Stuttering Severity Instrument Version IV (SSI-IV)

    This is an objective measure of stuttering in which it captures verbal samples of five minutes speaking during a conversation and 5 minutes of reading a passage.

    Time frame: This scale is completed on Visit 1/screening and Visit 5/week 8.

Secondary outcomes

  1. Clinical Global Impression Scale-Severity (CGI-S)

    This is an evaluation of the patient by the investigator as to whether or not the subjects has improved, remained the same, or worsened while in the study.

    Time frame: This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, and Visit 5/week 8.

  2. Subjective Stuttering Scale (SSS)

    Time frame: This scale is completed on Visit 2/baseline and Visit 5/week 8.

  3. Overall Assessment of the Speaker's Experience of Stuttering (OASES)

    Time frame: This scale is completed on Visit 2/baseline and Visit 5/week 8.

  4. Montgomery Asberg Depression Rating Scale (MADRS)

    An observer-rated depression scale

    Time frame: This scale is completed on Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8.

  5. Barnes Akathisia Scale (BAS)

    measures how restless the subject is during the examination

    Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.

  6. Abnormal Involuntary Movement Scale (AIMS)

    Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.

  7. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8.

  8. Simpson Angus Scale (SAS)

    Time frame: This scale is completed on Visit 1/screening, Visit 5/week 8.

07

Study locations

1 of 2 sites recruiting
  • CITrials
    Riverside, California 92506, United States
    Recruiting
  • University of California Riverside School of Medicine
    Riverside, California 92521, United States
    Not yet recruiting
08

References and documents

Publications

  • Maguire GA, Riley GD, Franklin DL, Maguire ME, Nguyen CT, Brojeni PH. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004 Apr-Jun;16(2):63-7. doi: 10.1080/10401230490452834. PubMed 15328899 ↗
  • Maguire GA, Yu BP, Franklin DL, Riley GD. Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother. 2004 Jul;5(7):1565-71. doi: 10.1517/14656566.5.7.1565. PubMed 15212606 ↗
  • Maguire G, Franklin D, Vatakis NG, Morgenshtern E, Denko T, Yaruss JS, Spotts C, Davis L, Davis A, Fox P, Soni P, Blomgren M, Silverman A, Riley G. Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study. J Clin Psychopharmacol. 2010 Feb;30(1):48-56. doi: 10.1097/JCP.0b013e3181caebbe. PubMed 20075648 ↗
  • Maguire GA, Riley GD, Yu BP. A neurological basis of stuttering? Lancet Neurol. 2002 Nov;1(7):407. doi: 10.1016/s1474-4422(02)00217-x. No abstract available. PubMed 12849360 ↗
  • Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014 Jan-Feb;37(1):26-30. doi: 10.1097/WNF.0000000000000017. PubMed 24434529 ↗
  • Riley J, Riley G, Maguire G. Subjective Screening of Stuttering severity, locus of control and avoidance: research edition. J Fluency Disord. 2004;29(1):51-62. doi: 10.1016/j.jfludis.2003.12.001. PubMed 15026214 ↗
  • Maguire GA, Riley GD, Franklin DL, Gottschalk LA. Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000 Aug;20(4):479-82. doi: 10.1097/00004714-200008000-00013. PubMed 10917410 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Aug 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2016
First posted
Sep 21, 2016
Start
Sep 2016
Primary completionEst.
Aug 2017
CompletionEst.
Nov 2017
Last update
Oct 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02909088
Lead sponsor
Gerald Maguire, MD
Collaborators
University of California Riverisde School of Medicine
Responsible party
Gerald Maguire, MD (Professor and Chair, Psychiatry and Neuroscience, Principal Investigator, CITrials) — Sponsor-investigator
First posted
Sep 21, 2016
Start date
Sep 2016
Primary completion
Aug 2017 (estimated)
Completion
Nov 2017 (estimated)
Last update
Oct 26, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecopipam

Start the discussion